Salix Files Crofelemer NDA As Napo Seeks To Terminate Their Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix submitted an NDA for HIV-associated diarrhea; it has exclusive rights to market the drug for that indication under a collaboration agreement with Napo but Napo claims Salix has breached the deal by delaying development and commercialization.